CHMP Backs Cosentyx for Adolescent Hidradenitis Suppurativa – Novartis Seeks First EU Biologic Approval in Patients Aged 12 and Older

Fineline Cube
4 Min Read
Summarize with AI

Novartis (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of secukinumab (Cosentyx) for the treatment of adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy. The recommendation would extend Cosentyx’s EU franchise into the adolescent HS population, an age group with limited treatment options for the chronic inflammatory skin disease.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyCHMP / EMA (European Union)
Opinion TypePositive opinion recommending approval
ProductCosentyx (secukinumab), fully human anti‑IL‑17A biologic
Proposed IndicationAdolescents ≥12 years with active moderate to severe HS with inadequate response to conventional systemic HS therapy
Announcement Date13 November 2026
Next StepsEuropean Commission final decision on the label extension, expected following the CHMP opinion

Drug Profile & Mechanism of Action

  • Molecule: Secukinumab (Cosentyx) – a fully human biologic that directly inhibits interleukin‑17A (IL‑17A), a key pro‑inflammatory cytokine driving HS pathogenesis.
  • Adult Indications (EU/global): Approved in adults for psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non‑radiographic axial spondyloarthritis (nr‑axSpA), hidradenitis suppurativa (HS), and polymyalgia rheumatica (PMR).
  • Pediatric Footprint: Approved in pediatric patients for PsO and juvenile idiopathic arthritis subtypes including juvenile psoriatic arthritis (JPsA) and enthesitis‑related arthritis (ERA); in the U.S., approved for pediatric patients ≥12 years with moderate to severe HS and for juvenile AS.
  • Disease Context: HS is a chronic, painful, inflammatory skin condition with onset frequently in adolescence; conventional systemic therapies offer limited efficacy, leaving substantial unmet need in younger patients.
  • Clinical Trial Data Underlying the EU Opinion: Not disclosed in the announcement.

Market Impact & Outlook

  • Franchise Expansion: The positive opinion positions Cosentyx to capture the adolescent HS segment in the EU, mirroring its existing U.S. approval in patients aged 12 and older – harmonizing the global pediatric HS footprint of Novartis’s flagship immunology asset.
  • Lifecycle Management: Extending into younger populations lengthens duration of therapy and reinforces Cosentyx’s standing across Novartis’s broadest immunology & inflammation portfolio spanning six adult indications.
  • Competitive Positioning: As one of the few biologics pursuing HS across adult and adolescent populations, Cosentyx would gain first‑mover advantage in EU adolescent HS should the European Commission endorse the CHMP recommendation.
  • Unmet Need Leverage: HS carries high psychosocial burden in adolescents; an approved biologic option for this cohort addresses a historically underserved market and supports payer engagement around early intervention.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review of Cosentyx in adolescent hidradenitis suppurativa, the anticipated European Commission decision following the CHMP opinion, label expansion, and commercial expectations. Actual results may differ due to risks including final regulatory determinations, clinical outcomes, market adoption, reimbursement decisions, and competitive dynamics.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *